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1. INTRODUCTION {#cas14518-sec-0001}
===============

Tyrosine kinase inhibitors (TKIs) markedly enhance the prognosis of patients with chronic myelogenous leukemia (CML), potentially enabling the attainment of a deep molecular response (DMR).[^1^](#cas14518-bib-0001){ref-type="ref"}, [^2^](#cas14518-bib-0002){ref-type="ref"} The life expectancy of patients with CML has become closer to that of the general population.[^3^](#cas14518-bib-0003){ref-type="ref"} Subsequently, the discontinuation of TKI became imperative to evade adverse events and the financial burden of TKI therapy that many patients with CML experience.[^4^](#cas14518-bib-0004){ref-type="ref"}, [^5^](#cas14518-bib-0005){ref-type="ref"}

In several studies, beginning with STIM1, nearly 40%‐60% of patients with chronic CML who sustained long DMR could discontinue TKIs and attain long‐term treatment‐free remission (TFR).[^6^](#cas14518-bib-0006){ref-type="ref"}, [^7^](#cas14518-bib-0007){ref-type="ref"} In addition, these studies proposed several predictive factors for successful discontinuation, including deeper molecular response, prolonged DMR duration, lack of prior TKI resistance, and higher numbers of natural killer (NK) cells before discontinuation.[^8^](#cas14518-bib-0008){ref-type="ref"}, [^9^](#cas14518-bib-0009){ref-type="ref"}, [^10^](#cas14518-bib-0010){ref-type="ref"}, [^11^](#cas14518-bib-0011){ref-type="ref"}, [^12^](#cas14518-bib-0012){ref-type="ref"}

In the Japanese multicenter prospective D‐STOP trial, dasatinib was discontinued following a 2‐year consolidation to sustain DMR in chronic CML to assess the TFR rate. Markedly, initial dasatinib specifically induces the elevation in lymphocytes, including large granular lymphocytes (LGL), NK cells, and cytotoxic T cells, as well as the decline in regulatory T cells (Tregs) in the early phase of treatment, related to early clinical responses.[^13^](#cas14518-bib-0013){ref-type="ref"}, [^14^](#cas14518-bib-0014){ref-type="ref"} A recent study has reported a correlation between the larger NK cell count before cessation and successful TRF.[^10^](#cas14518-bib-0010){ref-type="ref"}, [^12^](#cas14518-bib-0012){ref-type="ref"} Nevertheless, lymphocyte variations by dasatinib during sustained DMR before cessation is an area of growing interest. Previously, we reported that the more NK cells increased during dasatinib consolidation before discontinuation, the less successful would be TFR.[^15^](#cas14518-bib-0015){ref-type="ref"}

This study aims to present the final results of the D‐STOP trial, including the peripheral NK/T cell change during dasatinib consolidation associated with successful TFR.

2. MATERIALS AND METHODS {#cas14518-sec-0002}
========================

2.1. Study design and patients {#cas14518-sec-0003}
------------------------------

The D‐STOP trial (NCT01627132) is a multicenter, single‐arm, phase 2 study conducted at 22 centers in Japan. In this trial, patients diagnosed with chronic‐phase CML who attained DMR after receiving any TKI were eligible for 2‐year dasatinib consolidation therapy to sustain DMR. The inclusion criteria were as follows: age ≥ 15 years; performance status \[Eastern Cooperative Oncology Group score\] of 0‐2; and no severe primary organ dysfunction involving the liver, kidneys, or lungs. Of note, all prior treatments were permitted, except for allogeneic hematopoietic stem cell transplantation. The exclusion criteria were as follows: other chromosomal abnormalities besides the Philadelphia chromosome, a history of *BCR‐ABL1* mutation, and/or other active malignant disorders. The D‐STOP trial was approved by the Ethics Committees of all participating institutes. We obtained written informed consent from all participants per the Declaration of Helsinki guidelines. Between February 1, 2012, and January 31, 2014, 60 patients with a confirmed DMR were enrolled in the dasatinib consolidation phase.

2.2. Real‐time quantitative reverse transcription polymerase chain reaction (RT‐PCR) {#cas14518-sec-0004}
------------------------------------------------------------------------------------

During the dasatinib consolidation, we performed real‐time quantitative RT‐PCR (RQ‐PCR) every 3 months in the central laboratory \[Bio Medical Laboratories (BML), Tokyo, Japan\] to assess molecular responses based on the *BCR‐ABL1* International Scale (IS) and the laboratory\'s conversion factor, as described previously.[^16^](#cas14518-bib-0016){ref-type="ref"} Briefly, we used *ABL1* as an internal control, and the cutoff corresponded to *BCR‐ABL1* of 0.0069% IS or molecular response of 4.0 (a detectable disease with a *BCR‐ABL1* \< 0.01% IS or undetectable disease in cDNA with \> 10 000 *ABL1* transcripts). Subsequently, patients with DMR confirmation every 3 months during 2‐years consolidation entered the discontinuation phase. Following dasatinib cessation, DMRs were monitored by RQ‐PCR every month for the first year (clinical cutoff), followed by every 3 months for the remaining 2 years (a total of 3 years).

An additional RQ‐PCR was performed within 1 month if *BCR‐ABL1* \> 0.0069% IS was detected at any point during the consolidation or discontinuation phase. Two successive *BCR‐ABL1*‐positive results established a molecular relapse. For relapses during the discontinuation phase, dasatinib was restarted at the previously effective dose. After dasatinib recommencement, we assessed the response by RQ‐PCR after 1, 3, 6, and 12 months. Of note, dasatinib dose reduction was allowed at any time in response to adverse events at the physicians' discretion.

2.3. Flow cytometric analysis {#cas14518-sec-0005}
-----------------------------

We established the whole peripheral blood lymphocyte profiles by the central laboratory (BML) before and after 3, 6, 12, and 24 months of dasatinib consolidation. In addition, blood samples were collected more than a few hours after dasatinib intake. We measured peripheral white blood cell counts using an automated cell count analyzer. Flow cytometry methods are detailed elsewhere.[^13^](#cas14518-bib-0013){ref-type="ref"}, [^15^](#cas14518-bib-0015){ref-type="ref"} Briefly, the lymphocyte fraction was ascertained using forward‐scatter vs side‐scatter gating (Figure [S1](#cas14518-sup-0001){ref-type="supplementary-material"}),[^15^](#cas14518-bib-0015){ref-type="ref"} and immunophenotypic examinations were performed using two‐color or three‐color flow cytometry on a FACSCalibur System with CellQuest software, version 3.3 (Becton Dickinson, Franklin Lakes, NJ). All antibodies used in this study were purchased from Becton Dickinson. The defined lymphocyte subsets comprised NK cells (CD3^−^CD56^+^ and CD16^+^CD56^+^ cells), NK‐LGL (CD57^+^CD56^+^), helper T cells (CD4^+^CD8^--^), cytotoxic T cells (CD4^−^CD8^+^), T‐LGL (CD57^+^CD3^+^), and Tregs (CD4^+^CD25^+^CD127^low^)[^17^](#cas14518-bib-0017){ref-type="ref"} (Figure [S1](#cas14518-sup-0001){ref-type="supplementary-material"}B).

2.4. Endpoints {#cas14518-sec-0006}
--------------

In this study, the primary endpoint was the TFR rate at 12 months, defined as the percentage of patients with no dasatinib treatment without molecular relapse. To establish the TFR‐related predictive factors, we assessed patients by sex, age at discontinuation, Sokal risk score at diagnosis, duration of *BCR‐ABL1* transcript negativity before consolidation, TKI therapy duration before consolidation, total dasatinib dose, and type of TKI used when DMR was attained. In addition, we assessed the above‐described lymphocyte subsets before and after 3, 6, 12, and 24 months of dasatinib consolidation while in treatment‐free survival (TFS). Furthermore, safety was assessed throughout the consolidation period, and adverse events were classified using the Common Terminology Criteria for Adverse Events, version 4.0.

2.5. Statistical analysis {#cas14518-sec-0007}
-------------------------

In this study, we determined a sample size of, at least, 50 patients to illustrate that patients who discontinued dasatinib remained in TFS at a power \> 80%, when compared with data from a prior study.[^6^](#cas14518-bib-0006){ref-type="ref"} We separated each continuous variable into 2 groups using the cutoff points evaluated by the concordance index.

Using Kaplan‐Meier analysis, we calculated the proportion of patients in TFR; a log‐rank test was used to statistically compare the stratified groups (2 or more). In addition, Cox proportional hazards analysis of significant predictors in the univariate analysis was used to evaluate the factors contributing to successful discontinuation. Strongly correlated explanatory variables independently entered into the Cox regression model. Furthermore, factors significant in, at least, one of the tested models were considered possible independent predictors of relapse risk.

We generated receiver‐operating characteristic (ROC) curves to evaluate the cutoff values of the cell number change in each lymphocyte subset and clinical data for the Kaplan‐Meier analysis. Optimal thresholds along the ROC curves were ascertained by searching for plausible values where the sum of the sensitivity and specificity were maximized. We considered a *P*‐value \< .05 as statistically significant. All statistical analyses in this study were performed using the statistical software EZR on R commander (R Project for Statistical Computing, Vienna, Austria).[^18^](#cas14518-bib-0018){ref-type="ref"}

3. RESULTS {#cas14518-sec-0008}
==========

3.1. Patients\' characteristics {#cas14518-sec-0009}
-------------------------------

All patients in this study were followed up for ≥ 3 years after dasatinib discontinuation. Of 60 patients, 6 were excluded during consolidation because of consent withdrawal or variations in the *BCR‐ABL1* transcript levels suggestive of molecular relapse. The safety analyses revealed no severe (grade ≥ 3) treatment‐related toxic effects during the consolidation phase. Overall, 54 patients (32 males and 22 females) were enrolled in dasatinib discontinuation (STOP) phase as described earlier.[^15^](#cas14518-bib-0015){ref-type="ref"}

At treatment discontinuation, the median age of patients was 56 years (range: 27‐84 years) . In addition, the median duration of TKI treatment was 92 months (36‐177 months), and the median duration of *BCR‐ABL1* negativity before treatment cessation was 51 months (24‐173 months) . All patients were followed up for 36 months after discontinuation. Overall, 34, 19, and 1 patient(s) used imatinib, dasatinib, and an unknown agent, respectively, when attaining DMR before consolidation. Notably, no patient received interferon‐α.

3.2. TFS based on the patients\' characteristics {#cas14518-sec-0010}
------------------------------------------------

The estimated overall probabilities of TFS at 12 and 24 months were 63.0% \[95% confidence interval (CI): 48.7‐74.3\] and 59.3% (95% CI: 45.0‐71.0), respectively (Figure [1](#cas14518-fig-0001){ref-type="fig"}). Overall, 22 patients experienced relapses during discontinuation, and 20 patients relapsed within 7 months, except for 2 who relapsed 18 and 21 months after discontinuation. We observed the loss of major molecular response (MMR) in 20% of relapsed patients. All 22 relapsed patients responded to dasatinib retreatment within 3 months, thereby encompassing DMR achievement within 3, 6, 9, and 12 months in 13, 5, 2, and 2 patients, respectively.

![Estimated treatment‐free survival (TFS) in the D‐STOP trial. Estimated TFS of patients who discontinued dasatinib (*Y*‐axis) and the duration (mo) of discontinuation (*X*‐axis). Dotted line, 95% confidence interval (CI)](CAS-111-2923-g001){#cas14518-fig-0001}

In addition, we analyzed the clinical factors affecting molecular relapse during discontinuation (Table [1](#cas14518-tbl-0001){ref-type="table"}). We observed no significant correlation between the 12‐month TFS rate and patients' characteristics such as sex, Sokal score at diagnosis, *BCR‐ABL1* mRNA‐negative duration, TKI treatment duration, age at discontinuation, total dasatinib dose, and type of TKI used when DMR was attained by the univariate analysis.

###### 

Statistical analysis for factors affecting treatment‐free remission rates

                                                                                                                 Factors     TFR (%) (at 12 mo)   95% CI           Univariate analysis   Multivariate analysis                                
  -------------------------------------------------------------------------------------- ----------------------- ----------- -------------------- ---------------- --------------------- ----------------------- ------------- --- ---------- -----------
  Clinical factors                                                                       Gender                  M           56.2                 37.6‐71.3        1.83                  0.70‐4.77               .19                          
  F                                                                                      72.7                    49.1‐86.7   1.00                                                                                                             
  Age at discontinuation                                                                 \>56 y                  62.1        42.1‐76.9            1.00                                   .85                                                  
  [\<]{.ul}56 y                                                                          64.0                    42.2‐79.4   0.92                 0.38‐2.22                                                                                   
  Socal score                                                                            Low                     66.7        44.3‐81.7            1.00                                   .69                                                  
  Intermediate or High                                                                   58.8                    32.5‐77.8   1.22                 0.44‐3.36                                                                                   
  Duration of TKI treatment                                                              \>100 mo                78.9        53.2‐91.5            1.00                                   .18                                                  
  [\<]{.ul}100 mo                                                                        60.7                    40.4‐76.0   2.07                 0.66‐6.51                                                                                   
  Total dose of dasatinib                                                                [\<]{.ul}72 540 mg      69.6        46.6‐84.2            0.74             0.28‐1.96             .525                                                 
  [\>]{.ul}72 540 mg                                                                     63.0                    42.1‐78.1   1.00                                                                                                             
  BCR‐ABL1 mRNA‐negative duration                                                        \>50 mo                 77.8        51.1‐91.0            1.00                                   .122                    1                 .26        
  [\<]{.ul}50 mo                                                                         55.9                    37.8‐70.6   2.23                 0.74‐6.73                              2.35                    0.53‐10.52                   
  Type of TKI used at achieving DMR                                                      Imatinib                61.8        43.4‐75.7            1.09             0.43‐2.73             .85                                                  
  Dasatinib                                                                              63.2                    37.9‐80.4   1.00                                                                                                             
  Increase in the cell number of the lymphocyte subset during consolidation (cells/µL)   CD3^‐^CD56^+^NK cells   \>+376      26.7                 8.3‐49.6         1.00                                          .00096\*      1              .0064\*\*
  [\<]{.ul}+376                                                                          78.3                    55.4‐90.3   0.22                 0.074‐0.63                             0.032                   0.0027‐0.38                  
  CD16^+^CD56^+^NK cells                                                                 \>+241                  31.2        11.4‐53.6            1.00                                   .00054\*                1                 .011\*\*   
  [\<]{.ul}+241                                                                          85.0                    60.4‐94.9   0.15                 0.04194‐0.5515                         0.039                   0.0031‐0.48                  
  CD57^+^CD56^+^NK‐LGL cells                                                             \>+242                  36.8        16.5‐57.5            1.00                                   .0053\*                 1                 .010\*\*   
  [\<]{.ul}+242                                                                          77.3                    53.7‐89.8   0.26                 0.092‐0.76                             0.21                    0.065‐0.69                   
  CD8^+^CD4^‐^CTL cells                                                                  \>+212                  41.2        18.6‐62.6            1.00                                   .033\*                  1                 .14        
  [\<]{.ul}+212                                                                          76.5                    48.8‐90.4   0.32                 0.10‐1.03                              0.1759                  0.019‐1.77                   
  CD57^+^CD8^+^ T‐LGL cells                                                              \>+141                  41.7        15.2‐66.5            1.00                                   .153                                                 
  [\<]{.ul}+141                                                                          70.8                    48.4‐84.9   0.49                 0.17‐1.40                                                                                   
  CD4^+^CD8^−^ helper T cells                                                            \>−47                   63.2        37.9‐80.4            1.00                                   .785                                                 
  [\<]{.ul}−47                                                                           58.8                    32.5‐77.8   1.15                 0.40‐3.28                                                                                   
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3.3. Clinical data during D‐STOP study {#cas14518-sec-0011}
--------------------------------------

Adverse effect during consolidation has been already described.[^15^](#cas14518-bib-0015){ref-type="ref"} No patients withdrew from the study because of adverse effects before discontinuation. During the discontinuation phase, the adverse events ≥ G3 included gastrointestinal bleeding from colon diverticulum with anemia (G3) in 1 patient. Two arthralgia of extremities (G2) occurred in 2 patients, which may be considered TKI withdrawal syndrome.[^19^](#cas14518-bib-0019){ref-type="ref"}

3.4. Lymphocyte changes during consolidation therapy {#cas14518-sec-0012}
----------------------------------------------------

We assessed the lymphocyte changes conducted by dasatinib during consolidation. We defined TFR‐successful (S) or TFR‐failed (F) patients as those who had kept TFR \> 12 months or not \> 12 months. While the lymphocyte counts did not differ after consolidation between the S and F groups (*P* = .24), the relative lymphocyte counts were significantly increased only in the F group (*P* = .0026\*\*; Figure [2A](#cas14518-fig-0002){ref-type="fig"}).

![Changes in the numbers of total lymphocytes, natural killer (NK) cell subsets, and T cell subsets during consolidation therapy with dasatinib after attaining a deep molecular response (DMR). In all figures, the solid line indicates successful (S) patients who attained successful discontinuation without molecular relapse for \>12 mo; the dotted line denotes failed (F) patients who relapsed molecularly within 12 mo after discontinuation. Data are presented as averages ± standard errors (SE) as the graphs and data numbers described under the graphs. The *X*‐axis indicates the duration of consolidation (mo). The following data are presented on the *Y*‐axis during consolidation (*P*‐values were presented to compare the data to the baseline before consolidation). A, Numbers of the total lymphocytes in S and F patients. B, Increased numbers of CD3^--^CD56^+^NK cells compared with the baseline before consolidation. C, Increased numbers of CD16^+^CD56^+^ NK cells compared with the baseline before consolidation. D, Increased numbers of CD57^+^CD56^+^ NK‐LGL (large granular lymphocyte) cells compared with the baseline before consolidation. E, Increased numbers of CD8^+^CD4^--^ cytotoxic T cells compared with the baseline before consolidation. F, Increased numbers of CD57^+^CD3^+^ T‐LGL cells compared with the baseline before consolidation. G, Increased numbers of CD4^+^CD8^--^ helper T cells compared with the baseline before consolidation. H, Increased numbers of CD4^+^CD25^+^CD127^low^ Tregs compared with the baseline before consolidation](CAS-111-2923-g002){#cas14518-fig-0002}

Accordingly, we further assessed cell number changes in CD3^−^CD56^+^NK, CD16^+^CD56^+^NK, CD57^+^CD56^+^NK‐LGL, CD8^+^CD4^--^ cytotoxic T, CD4^+^CD8^--^ helper T, CD57^+^CD3^+^T‐LGL, and CD4^+^CD25^+^CD127^low^ Treg cells during consolidation.

3.5. Cell number changes in various T/NK cell populations during consolidation {#cas14518-sec-0013}
------------------------------------------------------------------------------

In this study, the cell number of CD3^‐^CD56^+^NK cells after 24‐month consolidation was significantly higher than the baseline before consolidation only in failed (F) patients (*P* = .0056\*\*) but not successful (S) patients (*P* = .98). However, the number after 12‐month consolidation in successful patients was higher than the baseline (*P* = .0094\*; Figure [2B](#cas14518-fig-0002){ref-type="fig"}). We observed similar tendencies in CD16^+^CD56^+^NK and NK‐LGL cells (Figure [2C and D](#cas14518-fig-0002){ref-type="fig"}).

In addition, the cell number of CD8^+^CD4^--^ cytotoxic T cells after 24‐month consolidation was higher than the baseline before consolidation only in failed (F) patients (*P* = .00024\*\*) but not successful (S) patients (*P* = .41), however the number after 12‐month consolidation in successful patients was higher than the baseline (*P* = .0014\*; Figure [2E](#cas14518-fig-0002){ref-type="fig"}). Notably, the results were similar in CD57^+^CD3^+^ T‐LGL cells (Figure [2F](#cas14518-fig-0002){ref-type="fig"}). Furthermore, CD4^+^CD8^--^ helper T cells did not change during consolidation in both S and F patients (Figure [2G](#cas14518-fig-0002){ref-type="fig"}). The changes in numbers of CD4^+^CD25^+^CD127^low^ Tregs tended to decline in both groups, although the decline in the S group was significant. (Figure [2H](#cas14518-fig-0002){ref-type="fig"}). In summary, CD3^‐^CD56^+^NK cells, CD16^+^CD56^+^NK cells, and NK‐LGL, as well as cytotoxic T and T‐LGL cells, were relatively increased throughout 24‐month consolidation only in F patients. In S patients; this relative increment transiently occurred after 12 months, but returned to the basal level after 24‐month consolidation (Figure [2B--F](#cas14518-fig-0002){ref-type="fig"}).

Moreover, patients with a higher elevation in CD3^−^CD56^+^NK \> +376 (/μL), CD16^+^CD56^+^NK \> +241 (/μL), and NK‐LGL cell counts \> +242 (/μL) after consolidation exhibited a significantly higher TFR rate after 12 months than others (*P* = .00096\*, 0.00054\*, and 0.00014\*, respectively) by univariate analysis (Table [1](#cas14518-tbl-0001){ref-type="table"}). These cutoff values were evaluated by ROC analysis. Likewise, those with the higher cell number elevation in CD8^+^CD4^--^ cells \> +212 (/μL) had higher TRF than others (*P* = .033\*).

Multivariate analysis using factors of *BCR‐ABL1*‐negative duration (\>50 months), elevation in cytotoxic T cells during consolidation (\> +212), and increase in NK cell subsets during consolidation (CD3^−^CD56^+^NK \> +376, CD16^+^CD56^+^NK \> +241, or NK‐LGL \> +242) were subsequently performed. A higher elevation in each NK cell subset correspondingly exhibited significantly higher TFR rates (*P* = .0064\*\*, .011\*\*, and .010\*\*, respectively; Table [1](#cas14518-tbl-0001){ref-type="table"} and Figure [3A‐C](#cas14518-fig-0003){ref-type="fig"}). Higher elevation in cytotoxic T cells tentatively correlated with longer TFR, but not significantly (Figure [3D](#cas14518-fig-0003){ref-type="fig"}).

![Estimated treatment‐free survival (TFS) according to the increase in the cell number of each NK cell subset during consolidation. TFS curves in patients with the higher or lower counts of each NK cell subsets. For the following comparative Kaplan‐Meier curves, the cutoff level was determined using a receiver‐operating characteristic (ROC) curve analysis as described in the Materials and methods section. A, TFS rates of patients with CD3^--^CD56^+^NK cell counts \> +376 cells or ≤ +376 cells at the end of consolidation, compared with the baseline before consolidation. B, TFS rates of patients with CD16^+^CD56^+^ NK cell counts \> +241 cells or ≤ +241 cells at the end of consolidation, compared with the baseline before consolidation. C, TFS rates of patients with CD57^+^CD56^+^ NK‐LGL cell counts \> +242 cells or ≤ +242 cells at the end of consolidation, compared with the baseline before consolidation. D, TFS rates of patients with CD8^+^CD4^--^ cytotoxic T cell counts \> +212 cells or ≤ +212 cells at the end of consolidation, compared with the baseline before consolidation](CAS-111-2923-g003){#cas14518-fig-0003}

4. DISCUSSION {#cas14518-sec-0014}
=============

For successful TKI discontinuation after sustained DMR in CML, some clinical factors, such as deeper molecular response, lengthier consolidation, and no prior resistance to TKI, are reported favorably[^8^](#cas14518-bib-0008){ref-type="ref"}, [^9^](#cas14518-bib-0009){ref-type="ref"}, [^10^](#cas14518-bib-0010){ref-type="ref"}, [^11^](#cas14518-bib-0011){ref-type="ref"}, [^12^](#cas14518-bib-0012){ref-type="ref"}. However such clinical factors were not always the same among studies because of their different clinical settings. The background conditions, such as immunological and genetic factors in CML, and surrounding cells should support these clinical factors. Recent studies have reported that immune effector recoveries, including NK and T cells, during sustained DMR under TKI are critical for TFR, as it might be used for immune surveillance against molecular relapse.[^20^](#cas14518-bib-0020){ref-type="ref"}, [^21^](#cas14518-bib-0021){ref-type="ref"}

Regarding lymphocyte responses to dasatinib, this study characterized the differences between those with or without successful TFR (\>12 months). In F patients with TFR ≤ 12 months, NK subsets, including CD3^−^CD56^+^NK, CD16^+^CD56^+^NK, and CD57^+^CD56^+^NK‐LGL, and T subsets, including CD8^+^CD4^--^ cytotoxic T cells and CD57^+^CD3^+^T‐LGL, increased relatively during the 24‐month consolidation, although those in S patients exhibited no significant changes after consolidation. Markedly, even in S patients, those subsets also increased transiently after 12‐month consolidation (Table [2](#cas14518-tbl-0002){ref-type="table"}).

###### 

Trends of relative change in each subset conducted by dasatinib in initial treatment before DMR or consolidation after DMR

  Relative change    Initial Dasatinib (1st or 2nd) before DMR   Dasatinib Consolidation (for sustained DMR)       
  ------------------ ------------------------------------------- --------------------------------------------- --- ---
  Whole lymphocyte   ↑ \[13\]                                    ↑                                             ↑   →
  CD56^+^ NK         ↑ \[13\]                                    ↑                                             ↑   →
  NK‐LGL             ↑ \[13\]                                    ↑                                             ↑   →
  T‐LGL              ↑ \[13\]                                    ↑                                             ↑   →
  Cytotoxic T        ↑ \[13\]                                    ↑                                             ↑   →
  Helper T           → \[13\]                                    →                                             →   →
  Treg               ↓ \[35\]                                    ↓                                             ↓   ↓
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Previously, we have reported the relative elevation in lymphocyte subsets, including CD14^−^CD56^+^NK, CD57^+^CD56^+^NK‐LGL, CD8^+^CD4^--^ cytotoxic T cells, and CD57^+^CD3^+^T‐LGL, before attaining DMR after initial dasatinib treatment as the second‐line therapy after imatinib.[^13^](#cas14518-bib-0013){ref-type="ref"} In the D‐STOP trial, the lymphocyte changes in F patients corroborated those patients in the report with large reactions to dasatinib (Table [2](#cas14518-tbl-0002){ref-type="table"}). The NK/T lymphocytes at diagnosis reportedly expanded clonally by initial dasatinib.[^14^](#cas14518-bib-0014){ref-type="ref"}

To date, the antileukemic functions of NK/T lymphocyte subsets remain partially elucidated. Perhaps, these proliferated lymphocytes might have a strong immunological effect on leukemic cells because early lymphocytosis correlated with an early clinical response such as attainment of DMR.[^13^](#cas14518-bib-0013){ref-type="ref"}, [^22^](#cas14518-bib-0022){ref-type="ref"}, [^23^](#cas14518-bib-0023){ref-type="ref"}

This study raised the question whether such elevated NK/T lymphocytes were really significant to maintain TFR. Even in patients with sustained DMR after TKI discontinuation, *BCR‐ABL1* DNA was detected, which may harbor minimal residual leukemia.[^24^](#cas14518-bib-0024){ref-type="ref"} Most primitive quiescent CML cells appear to be inherently resistant to TKI, and leukemic cell progressively remodels the endosteal bone marrow niche into a self‐reinforcing leukemic niche that impairs normal hematopoiesis and favors leukemic stem cell function.[^25^](#cas14518-bib-0025){ref-type="ref"}, [^26^](#cas14518-bib-0026){ref-type="ref"} Furthermore, immune effector responses were downregulated in CML patients at diagnosis.[^20^](#cas14518-bib-0020){ref-type="ref"} Failure to eradicate primitive quiescent CML cells may result in reinitiating malignancy after a period of latency.[^27^](#cas14518-bib-0027){ref-type="ref"} However, the immune system is not permanently compromised in CML. Effector responses had been restored to normal levels in CML patients who achieved MMR and DMR on TKIs compared with those at diagnosis.[^21^](#cas14518-bib-0021){ref-type="ref"} This suggested that there are staged recoveries of some immune responses in CML patients on TKI that may be linked to restrain quiescent CML cells.

The NK/T cells that expanded in response to dasatinib from diagnosis[^14^](#cas14518-bib-0014){ref-type="ref"} reportedly had antileukemic effects against CML cells,[^28^](#cas14518-bib-0028){ref-type="ref"}, [^29^](#cas14518-bib-0029){ref-type="ref"}, [^30^](#cas14518-bib-0030){ref-type="ref"} but had not been proven to have antileukemic effects against primitive quiescent CML cells. Sufficient restoration of normal immune effectors that are capable of suppressing primitive quiescent CML cells during DMR may be required for successful TFR. Dasatinib‐responsive NK/T cells that still remained during DMR may indicate that such immune reconstitution has not been completed in failed patients.

Perhaps, lymphocytosis by initial dasatinib occurs because of its possible off‐target effects[^31^](#cas14518-bib-0031){ref-type="ref"}. These were only in parallel with its direct action to *BCR‐ABL1* and early lymphocytosis and could suggest an early response to dasatinib, which has been already reported as good prognosis for other TKIs.[^32^](#cas14518-bib-0032){ref-type="ref"} In addition, lymphocytes in S patients had different, more silent, reactions to dasatinib after the 24‐month consolidation from those of F patients. This lymphocyte population should work functionally to suppress the primitive leukemic cell expansion, preventing molecular relapse after discontinuation. Markedly, even in S patients, lymphocyte reactions to dasatinib after 12‐month consolidation were much higher, corroborating those of F patients (Table [2](#cas14518-tbl-0002){ref-type="table"}). This might suggest that, during consolidation, the lymphocyte population with the higher response to dasatinib changed to give a lower response to dasatinib as observed in S patients after 24‐month consolidation. Reportedly, such immunological reconstitution was needed for successful TFR[^20^](#cas14518-bib-0020){ref-type="ref"}, [^21^](#cas14518-bib-0021){ref-type="ref"} and, thus, TFR tended to be more successful with the adequately longer period of sustained DMR.[^9^](#cas14518-bib-0009){ref-type="ref"}

In this study, some patients had already taken dasatinib before consolidation whereas others had taken imatinib. This difference might affect lymphocytic reactions to dasatinib during consolidation. To evaluate this, we presented lymphocyte counts (Figure [2A](#cas14518-fig-0002){ref-type="fig"}) and their fractions including CD3^−^CD56^+^, CD57^+^CD56^+^NK, and CD8^+^CD4^−^T cells from both TFR‐successful (TFR \> 12M) and TFR‐failed (TFR ≤ 12M) patients (Figure [S2](#cas14518-sup-0002){ref-type="supplementary-material"}). After consolidation, CD3^−^CD56^+^ and CD57^+^CD56^+^ NK fractions were significantly higher in failed patients whereas the CD8^+^CD4^−^T cell fraction was not. These results were consistent with this study.

In D‐STOP, patients with ≤ +242 CD3^−^CD56^+^NK cells or ≤ +376 NK‐LGL during consolidation had a significantly higher TFR (12M) rate compared with other patients (78.3% vs. 26.7% \[*P* = .0064\] and 77.3% vs 36.8% \[*P* = .010\], respectively) (Table [1](#cas14518-tbl-0001){ref-type="table"}).

Patients who had taken imatinib (imatinib → dasatinib) or dasatinib (dasatinib → dasatinib) before consolidation with ≤ +242 NK‐LGL during consolidation had a higher TFR (12M) rate than those patients with \> +242 NK‐LGL (91.3% vs. 33.3% \[*P* = .00643\] and 72.7% vs NA \[*P* = .001\], respectively) (Figure [4A and B](#cas14518-fig-0004){ref-type="fig"}). Patients who had taken imatinib or dasatinib before consolidation with ≤+376 NK‐LGL during consolidation tended to have a higher TFR rate than those with \> +376 NK‐LGL (84.6% vs. 38.5% \[*P* = .06\] and 80.0% vs. 33.3% \[*P* = .07\], respectively) (Figure [4C, D](#cas14518-fig-0004){ref-type="fig"}). The results in each population were comparable with this study. Therefore, the type of TKI (imatinib or dasatinib) before consolidation did not affect our results.

![The estimated treatment‐free survival (TFS) according to the increase in the cell number of each NK cell subset during consolidation. TFS curves were described as shown in Figure [3](#cas14518-fig-0003){ref-type="fig"}. TFS rates with CD3^--^CD56^+^NK cell counts \> +376 cells or ≤ +376 cells at the end of consolidation compared with the baseline before consolidation in patients who had taken imatinib (imatinib → dasatinib) (A) or dasatinib (dasatinib → dasatinib) before consolidation (B). TFS rates with CD57^+^CD56^+^ NK‐LGL cell counts \> +242 cells or ≤ +242 cells at the end of consolidation compared with the baseline before consolidation in patients who had taken imatinib (imatinib → dasatinib) (C) or dasatinib (dasatinib → dasatinib) before consolidation (D). Data of patients who achieved DMR by dasatinib after imatinib intolerance or resistance before consolidation were shown (E, F). As described in Figure [2](#cas14518-fig-0002){ref-type="fig"}, the solid line and dotted line indicate successful (S) without molecular relapse ≤ 12 mo and failed (F) patients with molecular relapse ≤ 12 mo, respectively. Data are presented as averages (± standard errors). The *X*‐axis indicates the duration of consolidation (mo). The following data are presented on the *Y*‐axis during consolidation (*P*‐values were presented to compare the data to the baseline before consolidation): E, number of CD3^‐^CD56^+^NK cells. F, relative increase (%) in number of CD3^--^CD56^+^ NK cells compared with the baseline before consolidation](CAS-111-2923-g004){#cas14518-fig-0004}

We considered here the reasons for differences in D‐STOP from findings in other discontinuation studies.

In this study, CD56^+^ NK cells were rapidly downregulated after dasatinib discontinuation, as seen in the DADI study[^10^](#cas14518-bib-0010){ref-type="ref"} (Imagawa, personal communication), and NK cells in successful patients seemed to become higher than those in failed patients without dasatinib treatment.[^15^](#cas14518-bib-0015){ref-type="ref"} Therefore, after elimination of dasatinib‐induced elevated NK cells after cessation, NK cell states seemed similar to that found for imatinib discontinuation.[^12^](#cas14518-bib-0012){ref-type="ref"}, [^33^](#cas14518-bib-0033){ref-type="ref"}

Of note, most NK cells expanded by dasatinib exhibited CD56^bright^ expression on their cell surfaces[^13^](#cas14518-bib-0013){ref-type="ref"} (Figure [S1](#cas14518-sup-0001){ref-type="supplementary-material"}), this result differs from the findings for immunologically powerful CD56^dim^ NK cells, as reported in imatinib discontinuation.[^12^](#cas14518-bib-0012){ref-type="ref"}, [^33^](#cas14518-bib-0033){ref-type="ref"} An imatinib discontinuation study reported higher NK cells just before discontinuation in S patients, but only higher CD56^dim^ functional NK cells resulted in a higher TFR rate, and, in contrast, higher immature CD56^bright^ NK cells correlated with a lower TFR rate.[^12^](#cas14518-bib-0012){ref-type="ref"}, [^33^](#cas14518-bib-0033){ref-type="ref"}

Therefore, we strongly suspected that the number of CD56^dim^ NK cells could be higher in successful patients than in failed patients.

To explore the difference between D‐STOP and DADI,[^10^](#cas14518-bib-0010){ref-type="ref"} we analyzed patients who achieved DMR by dasatinib after imatinib intolerance or resistance before consolidation in D‐STOP, because this population was similar to that of DADI. Interestingly, CD56^+^ NK cell count tended to be higher during consolidation in successful patients than failed patients in this population, consistent with DADI. This was not significant probably because of the small number of patients (Figure [4E](#cas14518-fig-0004){ref-type="fig"}). In contrast, increase in CD56^+^ NK cell during consolidation was clear only in failed patients in the population consistent with D‐STOP (Figure [4F](#cas14518-fig-0004){ref-type="fig"}). These results could explain the association between the 2 studies.

In dasatinib discontinuation, significance of NK cell count before cessation should be interpreted more carefully than imatinib discontinuation, because dasatinib elevated lymphocytes, particularly in NK cells, even after achieving DMR which at the small level was not regarded as lymphocytosis and NK cells rapidly downregulated after dasatinib cessation.[^10^](#cas14518-bib-0010){ref-type="ref"}, [^15^](#cas14518-bib-0015){ref-type="ref"} NK cell count before cessation might vary in situations such as prior imatinib intolerance or resistance and timing of dasatinib treatment. Actually, higher NK cells before dasatinib cessation led to successful TFR in DADI, but not First‐Line DADI.[^10^](#cas14518-bib-0010){ref-type="ref"}, [^34^](#cas14518-bib-0034){ref-type="ref"}

Regarding Tregs, dasatinib tended to downregulate these cells in both groups, especially in S patients. We previously demonstrated that first‐line dasatinib decreased Tregs not in the early period, but at later than 12 months.[^35^](#cas14518-bib-0035){ref-type="ref"} Thus, Tregs had different response patterns from other NK/T subsets, whose role for TRF seemingly warrants further investigation.

In this study, Treg, reported as negative regulators for NK/CD8^+^ T cells,[^36^](#cas14518-bib-0036){ref-type="ref"} tended to decrease during consolidation, consequently NK/CD8^+^ T cells increased during consolidation in F patients. However, these cells decreased, in contrast, during the latter half of consolidation in successful patients. One reason for this was that S patients probably gained more adopted NK/CD8^+^ T cells specific for leukemia. Actually, such adopted NK cells are reportedly more resistant to Treg regulation than canonical cells.[^37^](#cas14518-bib-0037){ref-type="ref"}

We previously showed NK cell differentiation that was associated with decrease in regulatory T cells.[^38^](#cas14518-bib-0038){ref-type="ref"} However, this relationship occurred until DMR was achieved. After DMR, we considered that altered immune reconstitution occurred in successful patients as described. Therefore, after DMR, another NK cell population such as CD56^dim^ NK cells that suppressed primitive quiescent CML cells for TFR might be responding to regulatory T cells, but not CD56^bright^ NK cells that we chiefly measured in this study.

Reportedly, immune reconstitution during sustained DMR is crucial, and included an elevation in mature NK cells and functional dendric cells, and decline in Treg, PD1^--^ T cells and myeloid‐derived suppressor cells in patients with CML during DMR.[^20^](#cas14518-bib-0020){ref-type="ref"}, [^21^](#cas14518-bib-0021){ref-type="ref"} In addition, the recovery of the marrow environment conducted by myeloproliferative disorders to normal marrow when keeping DMR could be crucial for TFR.[^26^](#cas14518-bib-0026){ref-type="ref"}, [^39^](#cas14518-bib-0039){ref-type="ref"} These studies support the significance of adequate, longer consolidation before discontinuation.

In conclusion, this study suggests that the silent reactions of NK/T peripheral lymphocyte subsets to dasatinib, especially NK subsets, during sustained DMR before discontinuation is vital for attaining longer TFR, perhaps because of more established immune surveillance in silent cells. Nevertheless, further investigation on its mechanism is warranted for more successful TFR.
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